Scinai Immunotherapeutics (SCNI) Other financing activities (2020 - 2026)
Scinai Immunotherapeutics (SCNI) posted Other financing activities of $151000.0 for Q1 2026, up 1272.73% sequentially from $11000.0 in Q2 2025, and up 15.27% YoY from $131000.0 in Q1 2025.
Scinai Immunotherapeutics (SCNI) Other financing activities (2020 - 2026) Analysis & Trends
Scinai Immunotherapeutics has reported Other financing activities for 6 years, with the latest figure at $151000.0 in Q1 2026.
- Quarterly Other financing activities rose 15.27% year-over-year to $151000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $293000.0 (up 94.04% YoY) and the FY2024 annual result came in at $1.4 million, up 52.16% from the prior year.
- Other financing activities rose to $151000.0 in Q1 2026 per SCNI's latest filing, from $11000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $5.7 million in Q4 2022 and troughed at -$4000.0 in Q3 2023.
- A 5-year average of $698916.7 and a median of $69500.0 in 2023 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2023 and 2024: Other financing activities plunged 300.0% in 2023, then jumped 1300.0% in 2024.
- Over 5 years, Other financing activities stood at $5.7 million in 2022, then plunged by 85.54% to $825000.0 in 2023, then slumped by 99.03% to $8000.0 in 2024, then jumped by 37.5% to $11000.0 in 2025, then soared by 1272.73% to $151000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $151000.0, $11000.0, and $131000.0 for Q1 2026, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Scinai Immunotherapeutics | 11.72 Mn | -3.10 Bn | -1.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 151,000.00 |
| Mar 31, 2026 | 151,000.00 |
| Jun 30, 2025 | 11,000.00 |
| Jun 30, 2025 | 11,000.00 |
| Mar 31, 2025 | 131,000.00 |
| Mar 31, 2025 | 131,000.00 |
| Sep 30, 2024 | 8,000.00 |
| Sep 30, 2024 | 8,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | 1.42 Mn |
| Mar 31, 2024 | 1.42 Mn |
| Dec 31, 2023 | 825,000.00 |
| Dec 31, 2023 | 825,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Jun 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -1,000.00 |
| Mar 31, 2023 | 127,000.00 |
| Mar 31, 2023 | 127,000.00 |